SLC5A2 and stage 5 chronic kidney disease: Antidiabetic drugs are known to inhibit the activity of glucose transporters, especially SGLT2, and this may be an effective therapy against renal diseases, such as diabetic nephropathy, chronic kidney disease, and end-stage renal disease.